FIND YOUR CONSULTANT
JOIN OUR COMMUNITY
FIND YOUR CONSULTANT
JOIN OUR COMMUNITY

Industries > 

Life Sciences > Biotechnology Practice > Coding Coverage And Reimbursement Strategy

Coding Coverage And Reimbursement Strategy

Service Line: Strategy

Finding the right consultant should be this easy.

1

Tell us about your project

2

Interview candidates

(We’ll provide bios within 48 hours on average)

3

Select your consultant and start work!

Find a consultant in our Biotechnology Practice

Prefer email? Write to [email protected]

Capability: Coding Coverage And Reimbursement Strategy

The following discussion illustrates a project that is well suited to the capabilities of an independent consultant in the Umbrex Biotechnology Practice. This is an illustrative example. Umbrex consultants adapt their methodology, timeline, and deliverables to the specific needs of each client.

1) Client Situation

The client operated within the therapeutics-focused biotech ecosystem and required support with Coding Coverage And Reimbursement Strategy in the context of Biotechnology. Teams across Emerging Therapeutic Biotech (Preclinical), Clinical-Stage Biotech (Phase I–III), Commercial Biotech (Post-Approval), Platform Biotech (Therapeutic Discovery), and Biotech Investors & Incubators sought a unified coding, coverage, and reimbursement playbook—HCPCS/CPT/ICD-10 strategies, compendia listings, and site-of-care economics—to secure coverage, appropriate payment, and patient affordability across the buy-and-bill and specialty pharmacy channels. The diagnostic surfaced concrete gaps and risks:

  • Fragmented coding pathways and prolonged “NOC” dependency
    • Claims were submitted under miscellaneous HCPCS (J3490/J3590/C9399) and temporary codes without a clear transition plan to permanent HCPCS (J- or Q-codes). Billing units and NDC-11 mappings were inconsistent, creating denials and write-offs. JW/JZ modifier usage for wastage lacked standardization.
  • Coverage policy uncertainty and slow payer uptake
    • National (NCD) and Local Coverage Determinations (LCDs) were not mapped; prior authorization (PA) criteria and clinical documentation requirements varied by payer and benefit channel. Compendia listings (NCCN, DRUGDEX, Lexicomp) were incomplete or misaligned with label, delaying coverage decisions.
  • Site-of-care economics not optimized
    • Facility vs. physician office economics and place-of-service (HOPD/ASC/office) were not modeled; OPPS APC and MPFS payment rates, infusion times, and drug administration coding (CPT 964xx/963xx) were inconsistently applied. White/brown bagging and site-of-care redirection policies were unmanaged.
  • Revenue cycle and claim edit issues
    • High first-pass denial rates tied to MUEs, NCCI edits, diagnosis-to-procedure mismatches, and incorrect revenue codes; limited use of billing modifiers (59, XE, JW/JZ) and condition codes; charge master and payer-specific edits were outdated or missing.
  • ASP/WAC, 340B, and pass-through dynamics not addressed
    • ASP lag dynamics and potential OPPS pass-through (C-codes) were not planned; 340B utilization and acquisition cost variance were not reflected in affordability and hub strategies; buy-and-bill economics at launch were underspecified.
  • Distribution and HUB readiness gaps
    • Limited distribution vs. open network decisions were delayed; benefit verification (BV), PA/appeals templates, and payer-specific documentation were ad hoc; accumulator/maximizer and copay policy impacts were not quantified.
  • Benefit routing ambiguity
    • Medical vs. pharmacy benefit positioning lacked a decision framework; J-code timing was not synchronized with specialty pharmacy channel setup, leading to access friction and abandonment.
  • Ex-US coding and tariff pathways unclear
    • EU-5 and other priority markets lacked mapped coding/payment routes (UK HRG, DE EBM/GOÄ/OPS/DRG, FR CCAM/ENCC/ATIH), stalling hospital budgeting and tenders.
  • Weak payer and provider tools
    • Field reimbursement lacked coding/billing guides, cost calculators, denial reason playbooks, and payer-specific objection handlers; provider training on documentation and coding was limited.
  • Underperforming KPIs
    • First-pass clean claim rate below 80%; average days-to-first-paid-claim exceeded targets; >50% claims billed under miscellaneous codes at 90 days post-launch; PA approval rates below plan; patient abandonment above benchmark; HUB BV turnaround times lagged; AR aging skewed to 60+ days; high volume of CO- and PR-denials tied to coding.

2) Project Objective

The primary objective focused on establishing a comprehensive coding, coverage, and reimbursement strategy—HCPCS/CPT/ICD-10 pathways, compendia listings, and site-of-care economics—to secure timely coverage, appropriate payment, and patient affordability across channels, while reducing denials and accelerating time-to-first-paid-claim.

Secondary objectives included:

  • Designing a J-code strategy (temporary to permanent) and interim NOC claims playbook with standardized units, NDC-11 mappings, JW/JZ usage, and payer edit navigation.
  • Securing compendia listings and aligning payer policy shaping (PA criteria, step edits, site-of-care rules) to clinical evidence and label.
  • Modeling site-of-care economics (OPPS/MPFS/ASC) and setting channel strategy (buy-and-bill vs. specialty pharmacy), including white/brown bag policy management.
  • Standing up HUB operations (BV, PA, appeals) with payer-specific templates, service-level expectations, and accumulator/maximizer mitigation.
  • Implementing revenue-cycle controls (charge master, claim edits, coding audits) and provider education to improve first-pass clean claims and reduce AR days.
  • Building dashboards with data lineage (837/835, denial codes, payer policy mappings) for continuous monitoring and root-cause remediation.
  • Equipping field reimbursement with coding/billing guides, cost calculators, and objection handlers; training internal teams and providers.
  • Creating ex-US coding/payment playbooks (UK, DE, FR and priority markets) to support hospital budgeting and tender readiness.

3) Methodology and Approach

Workstream 1: Coding Pathway Design and J-Code Strategy

We established end-to-end coding pathways from launch through permanent coding.

  • Activities we conducted:
    • Mapped launch coding: temporary C-codes (if eligible), miscellaneous HCPCS (J3490/J3590/C9399) usage, units per dose, NDC-11 mapping, and revenue codes; standardized JW/JZ wastage and modifiers per payer.
    • Drafted HCPCS Level II application package (descriptor, clinical usage, utilization projections, compendia references); sequenced biannual CMS/HCPCS cycles and commercial S-codes as needed.
    • Authored a transition plan from NOC to permanent J-/Q-code, including payer bulletins, provider education, and claim edit updates.
  • Tools/frameworks used: coding pathway map, J-code application checklist, unit conversion and NDC mapping guide, modifier matrix (JW/JZ/59/XE).
  • Stakeholders involved: coding/reimbursement, regulatory/medical, trade, field reimbursement, revenue cycle leaders.

Workstream 2: Coverage Policy and Compendia Alignment

We shaped coverage criteria and synchronized compendia listings with payer policies.

  • Activities we conducted:
    • Prioritized compendia submissions (NCCN, DRUGDEX, Lexicomp) with evidence alignment to label and real-world use; tracked review calendars and update cycles.
    • Mapped NCD/LCD status and payer policies across top plans; drafted clinical documentation and PA/appeal templates with required diagnoses (ICD-10-CM), labs, and concurrent therapies.
    • Developed payer engagement materials to align on PA criteria, step therapy exceptions, and site-of-care rules; coordinated medical affairs scientific exchange where appropriate.
  • Tools/frameworks used: policy matrix and compendia tracker, PA/appeal template library, payer objection/response bank.
  • Stakeholders involved: market access, medical affairs, HEOR, coding, payer account teams.

Workstream 3: Site-of-Care Economics and Channel Strategy

We quantified economics across settings and selected optimal routing.

  • Activities we conducted:
    • Modeled OPPS APC and MPFS drug admin codes (964xx/963xx), infusion times, overhead, and acquisition cost (WAC/ASP) scenarios; assessed pass-through status and site-neutral policy exposure.
    • Evaluated white/brown bag policies, specialty pharmacy vs. buy-and-bill economics, wastage assumptions, and inventory risk by site type; developed channel recommendations and contracting guardrails.
    • Built provider-facing cost calculators and billing examples to improve accuracy and predictability.
  • Tools/frameworks used: site-of-care P&L model, claim example library, channel decision framework, pass-through and ASP lag tracker.
  • Stakeholders involved: trade/distribution, pricing, field reimbursement, finance, provider relations.

Workstream 4: Revenue Cycle and Claims Optimization

We reduced denials and accelerated time-to-first-paid-claim.

  • Activities we conducted:
    • Reviewed charge master and payer-specific edits; implemented pre-adjudication claim edits for units, modifiers, and revenue codes; aligned diagnosis–procedure pairing and NCCI/MUE guidance.
    • Analyzed 837/835 data for denial taxonomy (CO-, PR-, PI- codes); built root-cause remediation and payer-specific playbooks; established clean-claim benchmarks and daily monitoring.
    • Coached provider billing teams; executed coding audits; instituted corrective action cycles and re-billing protocols for systemic issues.
  • Tools/frameworks used: denial heatmaps and RCA templates, claim edit ruleset, coding audit toolkit, clean-claim dashboard with lineage.
  • Stakeholders involved: provider billing/RCM, field reimbursement, HUB operations, analytics/IT.

Workstream 5: HUB, PA/Appeals, and Affordability Operations

We operationalized patient support and payer interactions to reduce abandonment.

  • Activities we conducted:
    • Stood up HUB SOPs for BV/PA/appeals with payer-specific documentation checklists; set SLAs and escalation ladders; integrated EDI/X12 where feasible.
    • Designed copay and patient assistance programs with compliance guardrails; modeled accumulator/maximizer impacts and mitigation; aligned foundation triage.
    • Instrumented HUB dashboards for BV turnaround, PA approval, appeal success, and abandonment drivers; linked to field reimbursement workflows.
  • Tools/frameworks used: HUB SOPs and KPI dashboards, PA/appeal template pack, affordability policy guide, patient journey map.
  • Stakeholders involved: patient services/HUB, legal/compliance, market access, field teams, specialty pharmacy partners.

Workstream 6: Field Reimbursement and Provider Education

We equipped field teams and providers with practical tools.

  • Activities we conducted:
    • Authored coding and billing guides (HCPCS/CPT/ICD-10-CM), cost calculators, and payer-specific quick sheets; created denial reason playbooks and sample documented medical necessity letters.
    • Trained field reimbursement and key sites on coding, documentation, claim edits, and PA evidence; established office hours for complex cases; launched feedback loops to update tools.
  • Tools/frameworks used: field toolkit library, provider webinar curriculum, case-study repository, objection handler scripts.
  • Stakeholders involved: field reimbursement, provider relations, medical affairs, coding specialists.

Workstream 7: Ex-US Coding/Payment Pathways (EU-5 Focus)

We prepared coding and tariff strategies for priority ex-US markets.

  • Activities we conducted:
    • Mapped UK HRG and reference costs; Germany EBM/GOÄ and DRG/OPS coding; France CCAM/ENCC/ATIH tariffs; coordinated with affiliates for hospital budgeting and tenders.
    • Developed localized billing guides and hospital economic models; aligned with HTA outcomes and procurement timelines.
  • Tools/frameworks used: EU coding/tariff playbooks, hospital budget impact calculators, affiliate training modules.
  • Stakeholders involved: affiliates (UK/DE/FR), global market access, hospital channel leads.

Workstream 8: Data, Dashboards, and Governance

We put in place monitoring, decision rights, and change control.

  • Activities we conducted:
    • Integrated HUB, specialty pharmacy, and 837/835 claims data; built KPI dashboards (clean claim rate, days-to-first-paid-claim, PA approval, abandonment, AR aging, % under NOC); documented data lineage and refresh cadence.
    • Set a reimbursement governance cadence (monthly steering, biweekly operational review); kept a decision log for coding changes, payer policy updates, and provider education priorities.
  • Tools/frameworks used: KPI dictionary with lineage, governance charter and decision log, change control SOPs, payer policy tracker.
  • Stakeholders involved: market access leadership, HUB/RCM, analytics/IT, field leadership, compliance.

4) Data Request

We requested datasets and artifacts necessary to design and execute coding, coverage, and reimbursement strategy. Typical horizons were 6–12 months pre/post launch for operational KPIs and current payer policy/compendia status.

  • Claims and billing:
    • 837/835 feeds with denial codes and remark codes; payer-level edit rules; charge master entries and revenue codes; units per dose and NDC-11 mapping tables; modifier usage (JW/JZ/59/XE); AR aging reports; clean claim rate by payer.
  • Payer policy and compendia:
    • NCD/LCD status by MAC; commercial policy summaries; PA criteria; step therapy requirements; site-of-care rules; compendia listings (NCCN, DRUGDEX, Lexicomp) and update calendars.
  • Pricing and acquisition:
    • WAC, ASP (historical and forecast), 340B mix, GPO contracts; specialty pharmacy contracts; white/brown bag policy summaries by payer and IDN.
  • Site-of-care and utilization:
    • Volume by place of service (HOPD, ASC, office); infusion times and administration codes used; pass-through status and APC groupings; MPFS rates.
  • HUB and SP operations:
    • Benefit verification volumes and turnaround; PA approval/denial reasons; appeal success rates; abandonment metrics and time-to-start; accumulator/maximizer impacts; call dispositions.
  • Field and provider feedback:
    • Common denial reasons; documentation gaps; payer-specific issues; coding audit findings; training attendance and results.
  • Ex-US inputs:
    • Tariff schedules (UK reference costs, DE DRG/EBM/GOÄ, FR CCAM/ENCC); hospital budget processes; country coding guides; affiliate policy watch.
  • Compliance:
    • MLR policies for field tools; anti-kickback and copay program guardrails; privacy constraints; data-sharing agreements with HUB/SP.

Common data pitfalls included inconsistent units and NDC mappings, missing modifier usage (JW/JZ), incomplete denial reason coding, outdated payer edit rules, gaps in compendia tracking, and siloed HUB/claims data without patient-level linkage. We established a data dictionary, payer policy tracker, and a controlled repository before modeling and tool deployment.

5) Questions for Client

  • What is the desired benefit routing at launch (medical vs. pharmacy) and under what conditions should we transition channels?
  • What is the timeline and risk tolerance for J-code application; what interim NOC strategy (units, modifiers, documentation) will you accept?
  • Which compendia listings are mission-critical for early coverage, and what evidence can we submit now vs. post-launch?
  • Which payers and IDNs represent the highest volume and policy risk; what PA criteria and site-of-care policies are negotiable?
  • What affordability posture do you intend (copay, PAP, foundation triage), and how should we handle accumulator/maximizer risk?
  • What pass-through, ASP lag, and 340B dynamics affect site-of-care economics; how should we message these to providers?
  • What HUB SLAs (BV TAT, PA approval target, appeal success, time-to-start) and data feeds are mandatory; how will compliance be governed?
  • What field reimbursement footprint and provider training cadence will you support; which KOL sites should be prioritized for coding pilots?
  • What dashboards and KPI thresholds will executives review (clean claim rate, days-to-first-paid-claim, PA approval, abandonment, % NOC, AR days), and what escalations should thresholds trigger?
  • What ex-US markets require first-wave coding/tariff playbooks; what affiliate resources and timing constraints exist?
  • What legal/compliance constraints govern copay design, white/brown bagging policies, and field tools?

6) Interview Guide for Subject Matter Experts

Head of Market Access / Reimbursement

  • Which payers/IDNs will drive early volume; where do you anticipate PA friction and site-of-care redirection?
  • What coverage criteria are acceptable; where will we push for step-therapy exceptions?
  • How should channel strategy balance buy-and-bill vs. SP given payer mix and white/brown bag policies?

Trade / Distribution Lead

  • What limited distribution network design and data feeds are feasible; how will SPs support BV/PA and adherence?
  • How will inventory, returns, and wastage be managed across settings; what controls exist for NDC serialization and DSCSA?

Coding & Billing / Revenue Cycle Lead (Internal or Provider)

  • Where do claims fail today (units, modifiers, diagnosis–procedure pairing, revenue codes); which payer edits cause the most denials?
  • What charge master updates and pre-adjudication edits are needed; how will we track clean-claim improvements?
  • What training and audit cadence is realistic for provider billing teams?

HUB / Patient Services Director

  • What BV/PA workflows, templates, and SLAs are in place; where do appeals succeed or fail?
  • How will we measure abandonment and time-to-start; what interventions reduce friction?
  • What compliance risks (kickback, data privacy) need guardrails in patient support?

Field Reimbursement / Provider Relations

  • Which provider pain points recur; what billing guides and calculators are most effective?
  • What payer objections and denial reasons need objection handlers; how do we equip sites for first-submission success?
  • How should we prioritize site training and KAM engagement?

Pricing & Finance

  • What ASP/WAC/340B dynamics affect gross-to-net; how sensitive are provider margins across settings?
  • What rebate structures or outcomes-based contracts intersect with coverage and payment?
  • What KPIs should tie to budget release and performance incentives?

Compliance / Legal

  • What MLR/PIE boundaries apply to field tools; what approvals are required for payer interactions?
  • What constraints govern copay/PAP, accumulator programs, and white/brown bag policies?
  • What documentation and audit trails are required for coding changes and payer policies?

7) Timeline

We executed a 12–14 week plan tailored to Coding Coverage & Reimbursement Strategy within Market Access & HEOR.

  • Weeks 1–2: Diagnostic and Strategy Setup
    • Assessed claims denials, coding usage, payer policies, compendia status, HUB SLAs, and site-of-care volumes; mapped J-code/NOC strategy, channel preferences, and ex-US priorities.
    • Decision Gate A: Approved coding pathway (NOC to permanent), compendia submission plan, payer/IDN priority list, and dashboard/KPI definitions.
  • Weeks 3–4: Coding/Policy Design and HUB Blueprint
    • Finalized NDC mappings, units, modifiers, revenue codes; drafted HCPCS application; prepared compendia submissions; authored HUB SOPs and PA/appeal templates; defined SP/LDD footprint and data feeds.
    • Decision Gate B: Ratified coding rules and HUB SLAs; authorized provider tool development and claims edit implementation.
  • Weeks 5–6: Site-of-Care Economics and Claims Optimization
    • Modeled OPPS/MPFS economics and channel strategy; deployed claim edit rules and charge master updates; launched clean-claim dashboards; initiated provider billing audits and training pilots.
    • Decision Gate C: Approved channel decisions and provider tools; set clean-claim targets and AR goals by payer.
  • Weeks 7–8: Payer Engagement and Field Enablement
    • Executed medical/payer engagements; submitted compendia updates; rolled out coding/billing guides, calculators, and denial playbooks; trained field reimbursement and top sites.
    • Decision Gate D: Validated PA approval uplift and denial reductions; confirmed readiness for J-code transition communications.
  • Weeks 9–10: HUB Operations and Affordability Launch
    • Activated HUB BV/PA workflows and dashboards; implemented copay/PAP programs with compliance guardrails; set accumulator/maximizer mitigation; integrated SP and HUB data feeds.
    • Decision Gate E: Cleared HUB performance; approved escalation ladders and response time SLAs; tuned affordability policies.
  • Weeks 11–12: Ex-US Playbooks and Governance Handoff
    • Delivered EU-5 coding/tariff playbooks; trained affiliates; finalized governance cadence, policy trackers, and decision logs; transitioned dashboards to steady-state owners.
    • Decision Gate F: Authorized steady-state operations; agreed quarterly policy reviews, coding updates, and KPI refreshes.
  • Weeks 13–14 (optional): Stress Tests and Audit Readiness
    • Stress-tested clean-claim performance across peak volumes; executed mock payer audits; prepared documentation for coding changes and compendia updates; refined risk register and contingency plans.

Critical path items included J-code application timing and interim NOC strategy, compendia listing cycles, payer policy negotiations, HUB readiness, claim edit deployment at providers, and data integration for KPI dashboards.

8) Deliverables

  • Coding Pathway and J-Code Application Pack
    • End-to-end coding map (launch to permanent), unit/NDC mapping rules, modifier matrix, revenue code guidance, and HCPCS application dossier with timelines.
  • Coverage Policy and Compendia Toolkit
    • Compendia submission templates and status tracker; payer policy matrix; PA/appeal templates; clinical documentation guides per payer.
  • Site-of-Care Economics and Channel Strategy
    • OPPS/MPFS/ASC models, pass-through scenarios, white/brown bag risk analysis, provider cost calculators, and channel decision framework.
  • Claims and Revenue Cycle Playbook
    • Charge master updates, claim edit rulesets, denial root-cause library, coding audit procedures, and clean-claim/AR dashboards with lineage.
  • HUB Operations and Affordability SOPs
    • BV/PA/appeal workflows, SLAs and escalation ladders, copay/PAP policies, accumulator/maximizer mitigations, and HUB performance dashboards.
  • Field Reimbursement and Provider Tool Suite
    • Coding/billing guides (HCPCS/CPT/ICD-10-CM), payer-specific quick sheets, denial reason playbooks, medical necessity letter templates, and training curriculum.
  • Payer Engagement and Communication Materials
    • Clinical policy shaping decks, PA criteria proposals, site-of-care guidance, and J-code transition communications for payers and providers.
  • Ex-US Coding & Tariff Playbooks (EU-5)
    • UK HRG/reference cost mapping, DE EBM/GOÄ/DRG coding, FR CCAM/ENCC tariffs, hospital budget impact tools, and affiliate training modules.
  • Dashboards and KPI Dictionary
    • Clean claim rate, days-to-first-paid-claim, PA approval, abandonment, % NOC vs. permanent code, AR aging; KPI definitions, formulas, sources, and refresh cadence.
  • Governance and Compliance Documentation
    • Decision logs, policy trackers, MLR-approved field tools, coding change control records, and audit-ready evidence for payer and compendia interactions.

9) Industry Insights

  • Speed to permanent coding drives uptake
    • A disciplined NOC-to-J-code plan—with standardized units, modifiers, and payer education—reduces denials and time-to-first-paid-claim. Aligning coding communications with compendia updates and payer policy cycles accelerates adoption.
  • Compendia listings remain pivotal
    • Many payers rely on NCCN/DRUGDEX/Lexicomp; early, accurate submissions synchronized with clinical evidence and label reduce policy lag and PA friction.
  • Site-of-care policies are tightening
    • White/brown bag mandates, site-of-care redirection, and site-neutral payment trends require proactive economics and contracting strategies; provider calculators and documentation support reduce friction.
  • Revenue cycle hygiene matters as much as coverage
    • Clean charge masters, payer-specific edits, and consistent modifier/unit rules lift first-pass rates; JW/JZ compliance and NCCI/MUE awareness prevent predictable denials.
  • ASP dynamics and pass-through can be leveraged
    • Monitoring ASP lag, seeking OPPS pass-through when eligible, and messaging provider margin scenarios help sustain buy-and-bill adoption during early quarters.
  • Accumulator/maximizer and affordability programs shape persistence
    • Designing copay/PAP within compliance guardrails and anticipating accumulator/maximizer impacts protect initiation and persistence in commercial plans.
  • Data lineage is non-negotiable
    • Payer and executive confidence depends on transparent KPI definitions, source mapping (837/835, HUB), and reproducible dashboards; lineage and audit trails reduce disputes and speed decisions.
  • Ex-US coding/tariffs require early alignment
    • UK HRG, DE EBM/GOÄ/DRG, and FR CCAM/ENCC pathways influence hospital budgeting and tenders; aligning with HTA outcomes and affiliate timelines avoids access delays.
  • What “good” looks like
    • A codified coding pathway with timely J-code; compendia listings synchronized to evidence; payer policy shaping with PA templates; site-of-care economics and channel strategy; HUB operations with clear SLAs; revenue cycle playbooks and provider tools; dashboards with lineage; and ex-US coding/tariff readiness.
  • Near-term watch points
    • OPPS/MPFS annual updates, sequestration changes, white/brown bag expansions, 340B policy shifts, prior authorization automation rules, compendia methodology updates, and ex-US tariff revisions. Quarterly policy reviews and coding updates sustain predictability and payment accuracy.

Implications for clients we served included enabling Emerging Therapeutic Biotech to launch with a credible NOC-to-J-code plan and provider toolset; supporting Clinical-Stage Biotech to synchronize compendia listings and payer policy shaping ahead of pivotal readouts; equipping Commercial Biotech to reduce denials, accelerate payment, and optimize site-of-care adoption; guiding Platform Biotech to standardize coding/coverage playbooks across partnered programs; and providing Biotech Investors & Incubators with diligence views on coding risk, payment predictability, and affordability exposure across portfolios.

Selected Capabilities of our Biotechnology Practice

Strategy & Corporate Development

  • Corporate Strategy And Growth Agenda: Define enterprise ambition, where to play and how to win, therapeutic area focus, build-partner-buy choices, and value creation roadmap for biotech platforms and asset-centric companies.
  • Portfolio Strategy And Indication Prioritization: Optimize pipeline across modalities using rNPV (risk-adjusted net present value), Probability of Technical and Regulatory Success, and constraints to prioritize indications, sequencing, and kill/hold decisions.
  • Business Development And Licensing Strategy: Set business development and licensing (BD&L) strategy, target screening, and out-licensing/in-licensing approach; shape deal thesis, valuation, and term sheets to maximize partnering value and optionality.
  • M&A Strategy And Diligence: Develop biotech mergers and acquisitions (M&A) strategy, longlist, shortlist, and theses; lead commercial, pipeline, and synergy diligence with integration blueprint and carve-out or asset-swap options.
  • Capital Allocation And Investor Readiness: Design capital allocation across programs and platforms; craft investor narrative, valuation, and financing strategy (venture, crossover, IPO) to extend runway and reduce cost of capital.

Operations

  • Manufacturing Operations Excellence: Improve yield, OEE, and right-first-time across upstream, downstream, and fill-finish to cut deviations, cycle time, and cost of goods for biologics and advanced therapies.
  • Tech Transfer And Scale-Up Execution: Plan and execute GMP tech transfer and scale-up, aligning control strategy and PPQ readiness to accelerate time-to-quality and de-risk commercial launch for new modalities.
  • Capacity Modeling And Debottlenecking: Model end-to-end capacity and cycle times, identify bottlenecks, and redesign schedules, changeovers, and cleanroom utilization to unlock throughput and defer capital for biotech facilities.
  • QC Release Cycle Time Reduction: Optimize QC labs with sampling rationalization, Laboratory Information Management System (LIMS), method lifecycle management, and scheduling to shorten batch release times and improve on-time-in-full service.
  • External Manufacturing Performance Management: Set governance with external manufacturing partners, KPIs, escalation, and issue resolution to improve on-time-in-full, right-first-time, and tech transfer outcomes while protecting supply.

Supply Chain

  • Integrated Business Planning And Supply Planning: Build integrated business planning with constrained supply planning and multi‑echelon inventory optimization to improve service, inventory turns, and adherence across drug substance and product networks.
  • Supply Network Design And Footprint Strategy: Optimize network of drug substance and drug product sites, distribution centers, and third‑party logistics to balance total landed cost, service, and risk in make‑buy‑location decisions.
  • Cold Chain And Temperature-Controlled Logistics: Design cold chain strategy, packaging, and lane qualification for 2–8°C, frozen, and cryogenic shipments; enable real‑time monitoring and excursion management to reduce spoilage and write‑offs.
  • Supply Risk And Shortage Management: Build multi‑tier risk mapping, dual‑sourcing strategies, and allocation playbooks with scenario planning and control‑tower alerts to prevent stockouts and manage biologics supply disruptions.
  • Cell And Gene Therapy Orchestration: Design vein‑to‑vein supply chain, chain of identity and custody, apheresis slot scheduling, and courier control to cut turnaround time and failure risk for autologous therapies.

Procurement & Strategic Sourcing

  • Category Strategy And Strategic Sourcing: Build category strategies for GMP raw materials, single-use assemblies, primary packaging; execute e-sourcing and negotiations to deliver Cost of Goods Sold (COGS) reduction and resiliency.
  • CDMO/CRO Vendor Selection And Contracting: Structure sourcing of Contract Development and Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs); set Quality Agreements; negotiate capacity, pricing, and protections to de-risk delivery.
  • Should-Cost Modeling And Clean-Sheet Costing: Develop should-cost models for single-use assemblies, chromatography resins, media, vials, and contract services to set target prices and win fact-based negotiations.
  • Supplier Risk And Continuity Planning: Conduct supplier and tier-2 risk assessments for plasmids, viral vectors, resins; secure long-term agreements, dual-source contracts, and indexation clauses to ensure continuity and price stability.
  • Supplier Relationship Management And Governance: Establish segmentation, joint business plans, Quarterly Business Reviews (QBRs), Key Performance Indicators (KPIs), and innovation pipelines to improve on-time-in-full, quality, and access to new technologies.

R&D & CMC

  • CMC Strategy And IND Readiness: Define phase-appropriate CMC strategy, control plans, and dossier-ready packages to accelerate IND (Investigational New Drug) submissions and de-risk early clinical manufacturing.
  • Process Development And Characterization: Design and optimize upstream and downstream processes using Design of Experiments, scale-down models, and process characterization to achieve titer, purity, and robustness targets pre-transfer.
  • Analytical Development And Method Lifecycle: Build potency, purity, identity, and safety assays; qualify and validate methods; design stability programs to enable release, comparability, and control of critical quality attributes (CQAs).
  • Formulation And Drug Product Development: Develop phase-appropriate formulations, excipient strategies, and container-closure systems for biologics, mRNA, and viral vectors to improve stability, usability, and shelf life.
  • Comparability And Post-Change Strategy: Plan comparability protocols, risk assessments, and bridging analytics for process changes, site moves, or scale-up to protect product quality and avoid clinical rework.

Organization

  • Operating Model And Organizational Design: Design stage-appropriate biotech operating model across R&D, CMC, Clinical, Quality, Supply, and Commercial; align structure, decision rights, and governance to accelerate development and launch.
  • Leadership And Governance Effectiveness: Strengthen executive cadence, board interfaces, decision forums, and RACI (Responsible, Accountable, Consulted, Informed) clarity to speed decisions, resolve cross-functional issues, and drive accountability.
  • Talent Strategy And Workforce Planning: Build capability maps, workforce plans, and location strategy for bioinformatics, process development, regulatory, and commercial roles to meet milestones while optimizing cost and flexibility.
  • Ways Of Working And Agile Implementation: Implement agile teams in R&D and CMC, meeting redesign, OKRs (Objectives and Key Results), and collaboration norms to increase throughput, transparency, and reduce cycle time.
  • Scaling From Virtual To Commercial Organization: Plan build-out of Quality, Supply, and Commercial functions; define roles, spans and layers, and shared services to scale efficiently before first launch.

Marketing

  • Brand Strategy And Positioning: Define biotech brand narrative, target segments, value proposition, and messaging architecture to differentiate in rare and specialty indications and drive HCP and patient preference.
  • Omnichannel HCP Engagement And Content Operations: Design omnichannel journeys, modular content, and channel mix across email, rep-triggered, web, and social to increase HCP reach, engagement, and conversion within regulatory constraints.
  • Key Opinion Leader And Community Influencer Strategy: Map and activate key opinion leaders (KOLs), digital opinion leaders; co-create education, publications, and advisory forums to build credibility and accelerate guideline inclusion and adoption.
  • Launch And Prelaunch Excellence: Build evidence-driven launch plans, disease awareness, patient-finding, and HCP activation; sequence milestones, content, and congresses to maximize share of voice and first-year uptake.
  • Marketing Performance And ROI Analytics: Build dashboards, marketing-mix models, and experimentation to attribute impact, optimize spend, and improve return on investment (ROI) across HCP, patient, and digital channels.

Pricing

  • Launch Pricing And Price Corridor Design: Define Wholesale Acquisition Cost (WAC) and ex-US list prices, price corridors, and price-volume curves by indication to balance access, uptake, and lifetime revenue.
  • Gross-To-Net Optimization: Diagnose rebate, chargeback, copay, 340B Drug Pricing Program (340B), Medicaid Best Price leakages; design contracting, accruals, and governance to improve net price and predictability.
  • Outcomes-Based And Innovative Contracting: Structure outcomes-based contracts, annuity payments, and warranties for gene and cell therapies; define metrics, data flows, and risk-sharing to secure access and net revenue.
  • International Reference Pricing And Launch Sequencing: Model cross-border reference rules, parallel trade, and price spillover; optimize country sequencing, tender posture, and corridors to protect global net price.
  • IRA And Price Renegotiation Readiness: Build Inflation Reduction Act (IRA) strategy, revenue risk scenarios, and negotiation playbooks; adjust contracting, launch timing, and portfolio mix to mitigate price erosion.

Sales

  • Field Force Sizing And Territory Design: Optimize field force size, territories, Customer Relationship Management (CRM) call plans, and routing to maximize healthcare professional (HCP) coverage and productivity for biotech specialty therapeutics.
  • Key Account Management Enablement: Establish Key Account Management (KAM) model for Integrated Delivery Networks (IDNs) and centers of excellence with planning, access pull-through, and cross-functional engagement to drive adoption.
  • Incentive Compensation And Sales Performance Management: Design compliant incentive plans, quotas, and scorecards; align to new patient starts, persistency, and access status to drive specialty biotech revenue growth.
  • Specialty Pharmacy And Hub Pull-Through: Orchestrate specialty pharmacy and patient support hub processes to reduce time-to-fill, improve benefits verification, and increase therapy initiation and adherence for complex treatments.
  • Sales Training And Field Readiness: Develop disease-state and clinical selling curricula, objection handling, and certification; equip field teams with compliant materials and tools to accelerate launch uptake and competitive wins.

Finance

  • FP&A And Runway Management: Build integrated cash, P&L, and scenario models; align to milestones and business development (BD) events; enable rolling forecasts to extend runway and optimize burn.
  • Product Costing And COGS Transparency: Establish standard costing, variance tracking, lot-level analytics, and transfer pricing to improve Cost of Goods Sold (COGS) predictability and margin decisions for biologics.
  • Working Capital Optimization: Optimize inventory policies, supplier terms, and collaboration cash schedules; redesign milestone invoicing to improve cash conversion cycle and fund critical programs.
  • Record To Report And Fast Close: Redesign close processes, chart of accounts, and Sarbanes-Oxley (SOX) controls to enable accurate inventory valuation, capitalization, and fast, audit-ready closes.
  • Collaboration And Revenue Recognition Advisory: Interpret Accounting Standards Codification (ASC) 606 for licenses, milestones, and cost-sharing; design policies, accruals, and systems to ensure compliant, audit-ready biotech revenue recognition and disclosures.

AI, Data & Analytics

  • Biotech Data Platform And Governance: Build FAIR, GxP-compliant data platforms with ontologies and master data to unify preclinical, CMC, clinical, and commercial datasets for analytics, interoperability, and data integrity.
  • CMC Digital Twins And Process AI: Develop bioprocess digital twins, multivariate control, and soft sensors to predict critical quality attributes, boost yield, and reduce deviations, cycle time, and cost.
  • Generative AI Copilots For CMC And Quality: Deploy large language models (LLMs) with Retrieval-Augmented Generation (RAG) for authoring, querying, and change-impact analysis; ensure validation, permissions, and audit trails in regulated environments.
  • RWE And Clinical AI For Trial Acceleration: Build real-world evidence pipelines and machine learning for patient finding, eligibility inference, and site selection to accelerate enrollment and improve protocol feasibility.
  • MLOps And Model Risk Management: Establish data pipelines, feature stores, versioning, monitoring, and validation with model risk controls and change management to safely scale AI in GxP settings.

Transformation

GxP Quality & Compliance

  • Quality Management System Design And Maturity Uplift: Design risk-based QMS aligned to ICH Q10; optimize SOPs, governance, roles, and metrics to meet GMP/GLP/GCP expectations and accelerate approvals and batch release.
  • Inspection Readiness And Remediation: Run risk-based inspection readiness with mock audits, storyboards, SME coaching, and day-in-the-life war rooms; lead remediation and CAPA plans to close FDA/EMA observations.
  • Data Integrity And Computerized Systems Assurance: Assess ALCOA+ data integrity, remediate gaps, and implement risk-based Computer Software Assurance; validate eQMS, LIMS, MES, and analytics with lifecycle controls and audit trails.
  • Deviation CAPA And Change Control Excellence: Redesign deviation, root cause analysis, CAPA effectiveness, and change control workflows; implement analytics and right-first-time behaviors to reduce recurrence, cycle time, and compliance risk.
  • External Partner Quality Oversight And Audits: Establish risk-based oversight for CDMOs, CROs, and suppliers; set Quality Agreements, audit programs, and release-by-exception to strengthen compliance, tech transfer outcomes, and supply reliability.

Program & Portfolio Management

Information Technology

  • IT Strategy And Enterprise Architecture: Define IT strategy, target architecture, and systems roadmap across ERP, MES, LIMS, QMS, CTMS, and EDC to enable scale, compliance, and faster launch readiness.
  • Core Systems Selection And Implementation Readiness: Run vendor selection for ERP, Veeva Vault Quality/Regulatory, MES, LIMS, and CTMS; define requirements, integrations, and implementation governance to de-risk delivery.
  • Cloud And Infrastructure Modernization: Design secure, GxP-ready cloud architecture on AWS or Azure, with network standards and disaster recovery, improving agility, reliability, and cost transparency.
  • Cybersecurity And Identity Management: Build cybersecurity program with risk-based controls, identity and access management, privileged access, and OT segmentation to protect patient data, intellectual property, and manufacturing assets.
  • IT Operating Model And Service Management: Design IT operating model, ITIL processes, and service catalog; establish SLAs, DevSecOps, and vendor management to improve service quality, delivery speed, and compliance.

Regulatory Affairs

  • Global Regulatory Strategy And Agency Engagement: Define IND/CTA-to-BLA/MAA strategy, pursue orphan, Breakthrough Therapy, Regenerative Medicine Advanced Therapy, and PRIME designations, and lead health authority interactions to de-risk development and approvals.
  • Submission Planning And eCTD Readiness: Build submission roadmap, authoring plan, Module 2/3 strategy, vendor/publisher governance, and quality checks to deliver first-cycle, on-time eCTD submissions across regions.
  • Labeling Strategy And Negotiation: Align Target Product Profile, evidence, and claims; lead core data sheet, USPI/SmPC development, negotiation strategies, and CCDS governance to secure competitive labels.
  • Post-Approval Lifecycle And Variations Management: Design regulatory pathways for post-approval changes; prepare supplements and variations, manage commitments, and harmonize dossiers to sustain global compliance and supply continuity.
  • Companion Diagnostic And Combination Product Regulatory Strategy: Define CDx co-development and combination product strategy, classification, and submission pathways; coordinate interactions with FDA device and drug centers to synchronize approvals and enable precision therapy access.

Clinical Development & Operations

  • Protocol Design And Operational Feasibility: Optimize protocol endpoints, eligibility, visit schedules, and assessments using feasibility and real-world data to cut screen failure, patient burden, cost, and cycle time.
  • Country And Site Strategy: Use epidemiology, investigator performance, and startup cycle time data to select countries and sites, set allocations, and build contingency to achieve predictable enrollment.
  • Patient Recruitment And Retention Acceleration: Deploy patient finding, referral networks, decentralized visits, eConsent, diversity plans, and travel support to accelerate enrollment, cut discontinuations, and improve last patient out predictability.
  • Risk Based Quality Management And Monitoring Optimization: Implement risk based quality management per Good Clinical Practice, central monitoring, tolerance limits, and source verification to lower queries, deviations, and monitoring cost.
  • CRO Oversight And Performance Management: Establish sponsor oversight aligned to Good Clinical Practice with KPIs, tolerance limits, issue escalation, and corrective action governance to improve CRO on-time delivery and quality.

Market Access & HEOR

  • Payer Value Proposition And Access Strategy: Define payer value proposition, unmet need, comparators, and access milestones; shape P&T and prior authorization criteria to secure rapid, broad coverage for specialty biologics.
  • Global HTA Strategy And Dossier Development: Develop global value dossier and AMCP dossier; plan NICE, G-BA, SMC, HAS submissions; tailor evidence and narratives to achieve first-cycle HTA approvals.
  • Health Economic Modeling And Evidence Synthesis: Build cost-effectiveness and budget impact models, partitioned survival or Markov; conduct indirect treatment comparisons and network meta-analyses to meet HTA and payer requirements.
  • Real-World Evidence For Value Demonstration: Design RWE strategy including registries, external control arms, and burden-of-illness studies; generate endpoints and PROs supporting HTA, ICER reviews, label expansions, and reimbursement renewals.
  • Coding Coverage And Reimbursement Strategy: Establish coding pathways, HCPCS/CPT/ICD-10 strategies, compendia listings, and site-of-care economics to secure coverage, appropriate payment, and patient affordability across channels.

Connect with the right consultant

Umbrex rapidly connects you with independent professionals who combine top‑tier consulting experience at firms such as McKinsey, Bain, Boston Consulting Group with hands‑on roles.

Find a consultant in our Biotechnology Practice

Prefer email? Write to [email protected]